{"analyses":[{"ciLowerLimit":"1.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.74","estimateComment":"Reference level = Hormone Therapy + Radiation Therapy","groupDescription":"Gray's test was used to compare cumulative incidence between treatment arms (1-sided significance level of 0.025) and the Fine-Gray model was used to calculate hazard ratios.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","paramType":"Hazard Ratio (HR)","paramValue":"1.86","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"94.3","upperLimit":"97.2","value":"95.7"},{"groupId":"OG001","lowerLimit":"90.8","upperLimit":"94.4","value":"92.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"987"},{"groupId":"OG001","value":"992"}],"units":"Participants"}],"description":"Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From registration to 10 years","title":"Disease-specific Survival Rate (10 Years)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}